文献速递毛发、甲与色素性疾病

利特昔替尼治疗斑秃期间实验室监测的临床价值:前瞻性真实世界队列研究

Clinical yield of laboratory monitoring during ritlecitinib treatment for alopecia areata: A prospective real-world cohort study.
PubMed 文献 · J Am Acad Dermatol · 2026-07-30

该前瞻性队列纳入162例12岁及以上接受利特昔替尼50 mg每日一次的斑秃患者,累计62.9患者年。61.1%出现至少1项治疗期间实验室异常,多发生于3个月内且以1级为主,无3级及以上异常,提示常规监测强度或可重新评估。

要点

  • 利特昔替尼治疗中实验室异常常见(61.1%),但以1级为主、无3级及以上。
  • 67.7%的首次异常发生在治疗3个月内。
  • 异常极少需要临床干预,支持重新考虑监测强度。

核心结论

  • 利特昔替尼治疗斑秃期间的实验室异常常见但轻微、罕有临床处理价值,支持重新考虑监测强度。

研究设计与样本

  • 前瞻性真实世界队列研究,纳入162例12岁及以上斑秃患者,接受利特昔替尼50 mg每日一次,累计62.9患者年。

主要发现

  • 99例(61.1%)出现至少1项治疗期间实验室异常,67例首次事件(67.7%)发生在3个月内。
  • 97例最高为1级异常,2例为2级,无3级及以上异常。

关键数值与推荐

  • 实验室异常按本地参考区间预设,并采用CTCAE 5.0分级。
  • 监测项目包括全血细胞计数、肝功能与肾功能参数。

临床怎么用

  • 可结合3个月内为异常高发期及以1级为主的特点,个体化调整实验室监测频率。

局限性

  • 单中心设计、中国人群队列、计划性监测不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Routine laboratory monitoring is recommended during Janus kinase inhibitor therapy, but its clinical yield in patients with alopecia areata has not been prospectively characterized. OBJECTIVE: To characterize the incidence, timing, severity, and clinical significance of laboratory abnormalities during ritlecitinib treatment. METHODS: In this prospective cohort, patients aged 12 years or older received ritlecitinib 50 mg once daily. Complete blood count, liver, and renal function parameters were assessed. Treatment-emergent abnormalities were predefined using local reference intervals and graded using Common Terminology Criteria for Adverse Events 5.0. Exploratory Cox regression was performed to identify factors associated with first laboratory abnormality. RESULTS: Among 162 patients contributing 62.9 patient-years, 99 (61.1%) developed at least 1 treatment-emergent laboratory abnormality; 67 first events (67.7%) occurred within 3 months. Abnormalities were predominantly mild: 97 patients had maximum grade 1 abnormalities, 2 had grade 2 abnormalities, and none had grade 3 or higher abnormalities. Prior systemic treatment was associated with higher hazard on univariable analysis (hazard ratio, 1.52; 95% confidence interval, 1.02-2.28; P = .041), but no independent predictor remained after multivariable adjustment. LIMITATIONS: Single-center design, Chinese cohort, and incomplete scheduled monitoring. CONCLUSION: Laboratory abnormalities during ritlecitinib therapy were common but mild and rarely actionable, supporting potential reconsideration of monitoring intensity.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Huang J, Zhang Z, Jian J, et al. Clinical yield of laboratory monitoring during ritlecitinib treatment for alopecia areata: A prospective real-world cohort study. J Am Acad Dermatol. 2026. PMID: 42532430. doi:10.1016/j.jaad.2026.07.089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。